Profilassi per Herpes Zoster ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
107若年性特発性関節炎1

107. 若年性特発性関節炎

臨床試験数 : 447 /  薬物数 : 297 - (DrugBank : 57) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 146
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2021-001577-24-IT
(EUCTR)		16/09/2021A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS)A two-cohort, open-label, single arm, multicenter study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics, of emapalumab in children and adults with macrophage activation syndrome (MAS) in Still’s disease (including systemic juvenile idiopathic arthritis and Adult onset Still’s disease) or with MAS in Systemic lupus erythematous - NI-0501-14 Macrophage activation syndrome (MAS) in the context of Systemic juvenile inflammatory arthritis (sJIA) and Adult onset Still’s disease (AOSD).MAS in the context of pediatric and adult Systemic lupus erythematous (SLE).
MedDRA version: 21.1;Level: PT;Classification code 10071583;Term: Haemophagocytic lymphohistiocytosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]		Product Name: Emapalumab
Product Code: [NI-0501]
INN or Proposed INN: Emapalumab
Product Name: Emapalumab
Product Code: [NI-0501]
INN or Proposed INN: Emapalumab
Product Name: Profilassi per Herpes Zoster
Product Code: [Profilassi per Herpes Zoster]
INN or Proposed INN: Antivirale ad uso diretto		Swedish Orphan Biovitrum AGNULLNAFemale: yes
Male: yes		41Phase 2;Phase 3United States;Czechia;Spain;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Belgium;Poland;Germany;Netherlands;China;Japan;Sweden